Context-specific protein tyrosine kinase 6 (PTK6) signalling in prostate cancer

Authors


Correspondence to: Angela L. Tyner, Department of Biochemistry and Molecular Genetics, University of Illinois College of Medicine, M/C 669, 900 South Ashland Avenue, Chicago, IL 60607, USA. Tel.: 312-996-7964; fax: 312-413-0353; e-Mail: atyner@uic.edu

Abstract

Background

Protein tyrosine kinase 6 (PTK6) is an intracellular tyrosine kinase that is distantly related to SRC family kinases. PTK6 is nuclear in normal prostate epithelia, but nuclear localization is lost in prostate tumours. Increased expression of PTK6 is detected in human prostate cancer, especially at metastatic stages, and in other types of cancers, including breast, colon, head and neck cancers, and serous carcinoma of the ovary.

Materials and methods

Potential novel substrates of PTK6 identified by mass spectrometry were validated in vitro. The significance of PTK6-induced phosphorylation of these substrates was addressed using human prostate cell lines by knockdown of endogenous PTK6 or overexpression of targeted PTK6 to different intracellular compartments.

Results

We identified AKT, p130CAS and focal adhesion kinase (FAK) as novel PTK6 substrates and demonstrated their roles in promoting cell proliferation, migration and resistance to anoikis. In prostate cancer cells, active PTK6 is primarily associated with membrane compartments, although the majority of total PTK6 is localized within the cytoplasm. Ectopic expression of membrane-targeted PTK6 transforms immortalized fibroblasts. Knockdown of endogenous cytoplasmic PTK6 in PC3 prostate cancer cells impairs proliferation, migration and anoikis resistance. However, re-introduction of PTK6 into the nucleus significantly decreases cell proliferation, suggesting context-specific functions for nuclear PTK6.

Conclusions

In human prostate cancer, elevated PTK6 expression, translocation of PTK6 from the nucleus to the cytoplasm and its activation at the plasma membrane contribute to increased phosphorylation and activation of its substrates such as AKT, p130CAS and FAK, thereby promoting prostate cancer progression.

Introduction

Prostate cancer is the most common form of cancer, other than skin cancer, in American men. About one out of six men will be diagnosed with prostate cancer during their lifetime. Although prostate cancer has a relatively low mortality rate, it remains the second leading cause of cancer-related deaths in American men [1]. The major cause of death is metastases resulting from lymphatic, blood or contiguous local spread. Unfortunately, we still lack effective means to treat metastatic prostate cancer, and the use of tyrosine kinase inhibitors is being explored as a treatment option [2, 3].

Roles for nonreceptor tyrosine kinases in prostate cancer have been previously reviewed [4]. SRC, FAK, JAK1/2 and ETK/BMX play indispensable roles in different aspects of prostate cancer including proliferation, migration, apoptosis and metastasis [4]. During the last few years, we have made substantial progress in understanding functions of the intracellular tyrosine kinase, protein tyrosine kinase 6 (PTK6), and its potential contributions to prostate cancer, and these new findings are reviewed here [5-9].

Protein tyrosine kinase 6 belongs to the PTK6 family of intracellular nonreceptor tyrosine kinases, which includes Fyn-related kinase (FRK, also known as RAK, BSK, Iyk and Gtk) and SRC-Related kinase lacking C-terminal regulatory tyrosine and N-terminal Myristoylation Sites (SRMS). These proteins are structurally similar to the SRC family kinases, consisting of Src-homology-3 (SH3) and SH2 domains followed by a tyrosine kinase catalytic domain. However, they lack an SH4 domain, which facilitates lipid modification and membrane association, and they exhibit flexibility in intracellular localization (reviewed in [10]). PTK6 family members share a highly conserved gene structure that is distinct from other intracellular tyrosine kinase families, including the SRC family [11, 12]. Human PTK6 was identified in cultured human melanocytes [13] and breast tumour cells [14] and has been commonly referred to as BReast tumour Kinase (BRK). Its mouse orthologue was cloned from normal small intestinal epithelial cell RNA in a screen for factors that regulate epithelial cell turnover, and was thus given the name SRC-related intestinal kinase (Sik) [15, 16].

Different roles for PTK6 in normal tissues and cancer

In normal tissues, expression of PTK6 is highest in the nondividing, differentiated epithelial cells of the gastrointestinal tract [16, 17]. PTK6 is also detected in other differentiated epithelial cells including those of the prostate [18], oral cavity [19] and skin [16, 20]. A variety of studies suggest that PTK6 negatively regulates proliferation and promotes the differentiation of epithelial cells. In the cultured human keratinocyte cell line HaCaT and embryonic mouse keratinocyte cell line EMK, addition of calcium promotes differentiation, which is accompanied by increased PTK6 expression and activation, and elevated levels of the epidermal differentiation markers, keratin-10 in HaCaT cells and filaggrin in EMK cells [20, 21]. Studies in a Ptk6-deficient mouse model demonstrated roles for PTK6 in promoting cell cycle exit and differentiation in the normal intestinal epithelium in vivo. Increased growth of small intestinal villi was accompanied by an expanded zone of proliferation and delayed enterocyte differentiation in Ptk6-/- mice [22].

Protein tyrosine kinase 6 also plays important roles in regulating the survival of normal cells in response to a variety of apoptotic stimuli. PTK6 sensitized immortalized nontransformed Rat1A cells to apoptosis induced by serum deprivation and UV irradiation [23]. Further in vivo studies revealed that PTK6 expression is induced in small intestinal crypt epithelial cells by γ-radiation, where it appears to promote DNA damage–induced apoptosis by inhibiting prosurvival signalling including AKT and ERK1/2 [24]. In the colon, induction of PTK6 in crypt base epithelial cells following administration of the carcinogen azoxymethane was also positively correlated with apoptosis [25].

Although PTK6 is not expressed in the normal human mammary gland, it is aberrantly expressed in a high percentage of breast tumours [26, 27]. Elevated expression of PTK6 has also been detected in other types of cancer including colon [17], prostate [8], head and neck cancer [28], serous carcinoma of ovary [29], lung [30] and thyroid cancer [31]. Recently, however, expression of PTK6 transcripts was found to be downregulated in oesophageal squamous carcinomas as a consequence of epigenetic modification, and PTK6 appears to have tumour suppressor activities in this type of cancer [32].

Several studies have demonstrated oncogenic roles for PTK6 using established cancer cell lines and animal models. PTK6 promotes breast cancer cell proliferation through phosphorylating and activating its substrates STAT3 [33] and STAT5b [34], and this process may be facilitated by STAP2 [35, 36], a scaffold protein that is also a PTK6 substrate. Interestingly, the suppressor of cytokine signalling 3 (SOCS3) has been identified as an inhibitor of PTK6 [37]. PTK6 phosphorylates paxillin and p190RhoGAP-A to promote EGF-dependent cell migration and invasion [38, 39]. PTK6 was identified from an siRNA screen as a critical regulator of IGF-1 mediated anchorage-independent survival of breast and ovarian tumour cells [40]. In addition, positive crosstalk between PTK6 and membrane receptors such as EGFR, HER2/Neu or MET has also been reported (reviewed in [10, 41-43]). Recently, PTK6 was shown to sustain EGFR signalling by directly phosphorylating EGFR and inhibiting its downregulation [44].

In a WAP-driven PTK6 transgenic FVB/N mouse model, delayed involution of the mammary gland might be caused by activation of a p38 MAPK prosurvival signalling pathway, and aged mice developed infrequent tumours with reduced latency compared with wild-type mice [27]. In the AOM/DSS (azoxymethane/dextran sodium sulphate) murine colon cancer model, disruption of Ptk6 impaired colon tumorigenesis, probably due to significantly reduced STAT3 activation [25].

While most available data suggest that PTK6 overexpression in cancer is oncogenic, some studies have correlated PTK6 expression with increased survival [45, 46] and tumour suppression [32]. This suggests that PTK6 could have more complex roles in cancer, which may be related to tumour heterogeneity and its intracellular localization and access to specific substrates. The ‘pro’-oncogenic role of PTK6 in most tumours and the ‘anti'tumorigenic role of PTK6 in normal cells might be achieved by activation of distinct signalling pathways due to cell/tissue type, PTK6 expression levels, alterations in intracellular location and different environmental stimuli. Oncogenic functions of PTK6 are enhanced when the protein is targeted to the plasma membrane in HEK-293 cells [47]. Our group first proposed that intracellular localization of PTK6 will have an impact on its cellular functions [18, 48], and discovered that nuclear-targeted PTK6 negatively regulates, whereas membrane-targeted active PTK6 enhances endogenous β-catenin/TCF transcriptional activity in SW620 colon cancer cells [49].

Aberrant expression, localization and activation of PTK6 in human prostate cancer

To understand the role of PTK6 in prostate cancer, we analysed the NCBI human genome microarray data set GDS2545, which contains 171 samples [50]. PTK6 mRNA levels were significantly higher in prostate tumour samples, especially in metastatic prostate tumour samples compared with normal prostate tissue and normal tissue adjacent to the tumour, indicating an oncogenic role for PTK6 in prostate tumorigenesis and metastasis [8].

Protein tyrosine kinase 6 is primarily localized within the nuclei of normal human prostate epithelial cells, but it is localized to the cytoplasm and at the membrane in poorly differentiated prostate tumours [18]. In the established human prostate cancer cell lines PC3 (Androgen Receptor/AR negative) and LNCaP (AR positive), the majority of PTK6 is localized within the cytoplasm, although nuclear PTK6 can also be detected by immunostaining in the more differentiated LNCaP cancer cell line [8, 18]. Prostate cancer cells provide a suitable system to investigate the biological significance of PTK6 translocation.

Interestingly, although only a small fraction of total PTK6 was localized in the membrane compartment in PC3 cells, membrane-associated PTK6 was highly phosphorylated at tyrosine residue 342, which is a marker for its kinase activation. In contrast, the more abundant pool of cytoplasmic PTK6 was not phosphorylated at this tyrosine residue. Targeting exogenous PTK6 with a mutation of its inhibitory tyrosine residue 447 (Y-F) to membrane compartments by addition of a palmitoylation/myristoylation consensus sequence (Palm) at the amino-terminus largely increases the active pool of PTK6 in PC3 cells [8]. In addition, compared with untargeted PTK6-YF, Palm-PTK6-YF (membrane-targeted) showed substantially higher activity in SYF cells (Src-/-, Yes-/-, Fyn-/- mouse embryonic fibroblasts) [8, 9]. These data indicate that membrane localization of PTK6 is critical for its activation and support the hypothesis that translocation of PTK6 from nucleus to cytoplasm/membrane in prostate cancer could promote its activation and access to different substrates. Understanding the regulation of this relocalization and activation of PTK6 could shed light on novel mechanisms that drive prostate tumorigenesis and metastasis.

Membrane-associated active PTK6 promotes prostate cancer cell migration by phosphorylating p130CAS and activating ERK5

To further understand PTK6 signalling mechanisms and identify new substrates, proteins whose phosphorylation was increased upon ectopic expression of active PTK6 in human cells were identified using liquid chromatography coupled with tandem mass spectrometry [9]. Along with the previously identified PTK6 substrates Sam68, paxillin and PSF, we identified several novel candidates, including p130 CRK-associated substrate (p130CAS) [8] and focal adhesion kinase (FAK) [9], and further demonstrated that PTK6 directly phosphorylates them in vitro. p130CAS is a scaffolding protein that includes a domain containing 15 repeats of a YXXP motif that can be targeted by SRC family kinases [51]. Tandem mass spectrometry revealed 11 tyrosine residues within the substrate domain that can be targeted by PTK6 in vitro [8]. FAK is also a multidomain protein that can be phosphorylated by SRC family kinases at several tyrosine residues including 576/577, 861 and 925. Phosphorylation of tyrosine residues 576 and 577 is crucial in achieving maximum kinase activity, while phosphorylated tyrosine residue 925 is believed to be a high-affinity Grb2 binding site (reviewed in [52]). Tandem mass spectrometry analyses showed that PTK6 phosphorylates FAK at tyrosine residue 861 in vitro, although the biological significance of the phosphorylation on this residue is not clear [9].

Both p130CAS and FAK are concentrated at focal adhesions [53, 54]. Following integrin clustering, FAK phosphorylates p130CAS at its C-terminal Y664DYVHL motif and then SRC phosphorylates p130CAS at several tyrosine residues within its substrate domain, which provide binding sites for the adaptor protein CRK, leading to the activation of the small GTPase RAC that is able to induce membrane ruffling, cytoskeleton remodelling and cell migration [55, 56]. Expression of membrane-targeted active PTK6 in PC3 cells induced membrane ruffling and formation of specific structures called peripheral adhesion complexes, which have been observed in active SRC-expressing KM12C colon cancer cells [8, 57]. Both the kinase activity and membrane localization of PTK6 are necessary for the formation of peripheral adhesion complexes. Tyrosine phosphorylation of p130CAS and FAK are both induced and enriched in these structures [8]. Interestingly, the formation of peripheral adhesion complexes induced by PTK6 is dependent on p130CAS but not FAK, as knockdown of p130CAS impaired their formation, but knockdown of FAK did not. It is possible that PTK6, unlike SRC, does not rely on FAK to initiate the phosphorylation at the YDYVHL motif of p130CAS [8].

We also demonstrated that ERK5 but not ERK1/2 is enriched in peripheral adhesion complexes induced by membrane-targeted active PTK6. Knockdown of p130CAS impaired ERK5 activation in response to serum stimulation, indicating that ERK5 is activated downstream of p130CAS [8]. p130CAS may serve as a scaffold protein that provides multiple phosphorylated tyrosine residues as binding sites for downstream interacting partners, to convey the Palm-PTK6-YF induced oncogenic signalling. It has been reported that PTK6 forms complexes with ERK5 in various human cells [58], but whether p130CAS and ERK5 are in the same complex is not known. As with other focal adhesion-like structures such as invadopodia and podosome, formation of peripheral adhesion complexes is accompanied by increased cell migration. This is dependent on p130CAS and ERK5, as knockdown of either protein impaired the formation of peripheral adhesion complexes and cell migration [8].

Activation of PTK6 at the membrane protects cells from anoikis through activation of FAK and AKT survival signalling

Membrane-targeted active PTK6 is able to transform murine embryonic fibroblasts, even in the absence of the SRC family kinases Src, Yes and Fyn. One of the most striking features of Palm-PTK6-YF-transformed SYF cells is their ability to overcome anoikis and maintain proliferation under suspended growth conditions. Palm-PTK6-YF-mediated FAK phosphorylation and the subsequent activation of AKT survival signalling contribute to this process [9].

In the absence of FAK, Palm-PTK6-YF was still able to protect Fak-/- MEFs from anoikis, indicating it has the ability to activate survival signalling independent of FAK. However, stable co-expression of FAK and Palm-PTK6-YF in Fak -/- MEFs synergistically activated AKT survival signalling and protected cells against anoikis. These data demonstrated that, while not essential, FAK is involved in PTK6-meditated anoikis resistance. Interestingly, Palm-PTK6-YF failed to protect Akt1/2-/- MEFs from anoikis, suggesting AKT is a critical downstream player that mediates survival signalling induced by PTK6 or FAK activation [9].

PTK6 directly phosphorylates AKT at tyrosine residues and promotes its activation

AKT is a direct substrate of PTK6. Tandem mass spectrometry analysis revealed that tyrosine residues 215 and 326 of AKT can be phosphorylated by PTK6. Further point mutation studies demonstrated that tyrosine residues 315 and 326 of AKT are the primary targets of PTK6, residues that can also be phosphorylated by SRC [7, 59]. Importantly, PTK6 induced the tyrosine phosphorylation of AKT in SYF cells, which lack endogenous Src, Yes and Fyn. In the presence of exogenous PTK6, SYF cells have increased levels of AKT activation (marked by phosphorylation of Threonine 308 and Serine 473) in response to physiological levels of EGF, which is accompanied by increased AKT tyrosine phosphorylation. SYF cells expressing active PTK6, but not kinase-dead PTK6, showed increased cell proliferation [7].

Knockdown of endogenous PTK6 impairs tumorigenicity of prostate cancer cells

Protein tyrosine kinase 6 is primarily localized within the cytoplasm in the highly tumorigenic PC3 prostate cancer cell line [8]. Stable knockdown of PTK6 in PC3 cells using two different shRNA constructs impaired cell proliferation and colony formation [5]. PTK6 also plays an important role in cell migration, as transient knockdown of PTK6 using siRNAs largely decreased cell migration, which was accompanied by decreased p130CAS phosphorylation and ERK5 activation [8]. Moreover, PTK6 is primarily responsible for the anoikis resistance of metastatic prostate cancer PC3 cells, which are able to maintain an ~80% survival rate under suspended growth conditions for 8 days [9]. Knockdown of PTK6 in PC3 cells induced apoptosis under suspended growth conditions, which was accompanied by reduced FAK and AKT activation [9]. Interestingly, while PTK6 and SRC share several common substrates, knockdown of SRC in PC3 cells had only a small impact on the anoikis resistance of PC3 cells, and knockdown of both SRC and PTK6 did not have a synergistic effect, indicating PTK6 is the key player in protecting prostate cancer cells from anoikis [9]. These data demonstrate the oncogenic role of PTK6 in various aspects of tumorigenicity, including growth, survival and cell migration, and suggest that targeting PTK6 might be beneficial in treating human prostate cancer.

Introducing PTK6 into the nucleus of PC3 cells negatively regulates growth

Knockdown of PTK6 in PC3 cells led to growth inhibition, supporting a growth-promoting role for endogenous cytoplasmic PTK6 in this prostate cancer cell line. However, re-introduction of ectopic PTK6 into the PC3 cell nucleus by addition of a SV40 nuclear localization signal to the amino-terminus of PTK6 also led to growth inhibition that was dependent upon PTK6 activity [5]. These data suggest that nuclear PTK6 is important for maintaining proper growth regulation in the normal prostate.

Different functions for PTK6 within the nucleus and at the membrane could be explained by its access to unique sets of substrates and interacting proteins in the different compartments. Sam68, a known PTK6 substrate [60], is a multifunctional KH domain–containing protein with several proline-rich motifs that has context-specific RNA-binding and adaptor protein functions [61, 62]. It is largely nuclear in normal prostate and prostate tumours [18], and is phosphorylated on tyrosine residues by nuclear-targeted PTK6 [5]. Sam68 has been implicated in development of prostate cancer. Expression of Sam68 was increased in 35% of prostate cancer samples examined, and knockdown of Sam68 led to reduced proliferation of cultured prostate cancer cells [63]. Nuclear PTK6 in the normal prostate may inhibit growth by increasing tyrosine phosphorylation of Sam68 and related RNA-binding proteins, leading to inhibition of their RNA-binding activities and affecting different aspects of RNA metabolism, including RNA stability, translation and transport [5, 60]. Following its relocalization to the cytoplasm/membrane in prostate cancer, PTK6 would no longer have access to nuclear Sam68 (Fig. 1).

Figure 1.

Distinct functions for protein tyrosine kinase (PTK6) in the nucleus and at the plasma membrane. In normal prostate epithelial cells, total and active PTK6 is enriched in the nucleus where it has access to specific nuclear substrates and interacting proteins. These include the RNA-binding proteins Sam68 [60] and SLM1 and SLM2 [48], as well as β-catenin [49]. PTK6 inhibits the RNA-binding abilities of Sam68 [60] and the transcriptional activities of β-catenin [49]. Relocalization of PTK6 from nucleus to cytoplasm in prostate cancer facilitates its activation at the membrane. Active PTK6 can then phosphorylate and activate its cytoplasmic and membrane substrates including p130CAS [8], FAK [9], AKT [7] and β-catenin [49] to promote cancer cell proliferation, survival and migration.

Protein tyrosine kinase 6 can also interact with and phosphorylate β-catenin on multiple tyrosine residues [49]. β-catenin, which has distinct membrane and nuclear functions, regulates both cell adhesion and transcription [64]. It is a key component of the WNT signalling pathway that is involved in promoting prostate cancer progression [65]. Nuclear-targeted PTK6 was shown to inhibit β-catenin-/TCF-regulated transcription in colon cancer cells [49]. In contrast, expression of membrane-targeted active PTK6 led to increased β-catenin-/TCF-regulated transcription [49]. At the membrane, PTK6 can phosphorylate β-catenin on tyrosine residue 142, inhibiting its membrane and promoting its nuclear functions [49] (Fig. 1). Differential regulation of β-catenin would provide another mechanism by which nuclear PTK6 could inhibit, while membrane-associated PTK6 could promote prostate epithelial cell proliferation, and requires further investigation.

Potential mechanisms underlying PTK6 translocation: a role for the alternative PTK6 transcript ALT-PTK6?

Protein tyrosine kinase 6 lacks both membrane and nuclear targeting signals, but it is largely nuclear in normal prostate epithelium and cytoplasm/membrane associated in prostate cancer [18]. A particularly interesting question that still needs to be addressed is, ‘How does PTK6 translocate from the nucleus to the cytoplasm during the development/progression of prostate cancer?’ We determined that translocation is not due to aberrant nuclear export mediated by Crm-1/exportin-1, because inhibiting Crm-1/exportin-1 using leptomycin B did not result in nuclear accumulation of PTK6 in PC3 cells. Moreover, overexpression of Sam68, a nuclear binding partner of PTK6, was not sufficient to bring PTK6 into the nucleus [5].

Interestingly, expression of ALT-PTK6, which is encoded by an alternatively spliced PTK6 transcript, is able to affect the intracellular localization of exogenous PTK6 in HEK-293 cells. ALT-PTK6 contains the intact SH3 domain of PTK6 and could compete with PTK6 for binding of specific cytoplasmic substrates and binding partners. In cotransfection studies, increased ectopic expression of ALT-PTK6 led to increased nuclear localization of full-length active PTK6 and inhibition of β-catenin/TCF transcription. ALT-PTK6 may compete with full-length PTK6 for binding to a cytoplasmic retention factor that has yet to be identified, allowing PTK6 to re-enter the nucleus and inhibit β-catenin-induced transcription [6]. ALT-PTK6 expression is decreased in human prostate cancer samples, which may enhance the cytoplasmic retention and oncogenic signalling of PTK6 [6].

Conclusions

Functions of PTK6 are highly context dependent and distinct in normal tissues and cancer. Increased growth, impaired enterocyte differentiation [22] and impaired DNA damage–induced apoptosis [24] led to the hypothesis that PTK6 might act as a tumour suppressor in the intestine. Surprisingly, Ptk6 null mice were resistant to AOM/DSS-induced colon tumorigenesis refuting this notion [25]. However, recent studies suggest that PTK6 functions as a tumour suppressor in oesophageal squamous cell cancers [32]. In contrast, oncogenic roles for PTK6, particularly in breast cancers (reviewed in [10, 41]) are supported by a large body of data. Identified inhibitors of PTK6 that may have therapeutic potential under the appropriate conditions include the BRAF inhibitor PLX4032 [66], Geldanamycin, an Hsp90 inhibitor [67], SOCS3 [37] and a series of substituted imidazo[1,2-a]pyrazin-8-amines [68].

The prostate provides a unique model where the importance of PTK6 expression levels and intracellular localization can be addressed. Increased expression, altered intracellular localization and activation at the plasma membrane are characteristics of PTK6 in prostate cancer. These characteristics may promote its access to distinct cytoplasm- and membrane-associated substrates and interacting proteins including AKT [7], β-catenin [49], p130CAS [8], and FAK [9]. PTK6-mediated phosphorylation and/or association with these proteins could lead to the activation of oncogenic signalling pathways that are involved in regulating cell growth, survival and migration, therefore promoting prostate cancer progression. The relocalization of PTK6 and its activation in different cellular compartments could serve as a marker for cancer staging and prognosis. Recently, we demonstrated that targeting PTK6 enhances the response of colon cancer cells to chemotherapeutic agents [69]. Studies in prostate cancer cells suggest that targeting PTK6 in prostate cancer may also have significant therapeutic benefits.

Acknowledgements

A.L.T. is supported by NIH grant DK44525, DOD grant PC110752 and pilot funding from the University of Illinois Cancer Center. We thank Patrick Brauer (University of Toronto), Zebin Wang, Maoyu Peng, Priya Mathur and Ben Hitchinson (University of Illinois at Chicago) for their helpful comments and suggestions.

Address

Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, M/C 669, 900 South Ashland Avenue, Chicago, IL 60607, USA (Y. Zheng and A. L. Tyner).

Ancillary